Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

For more information, or to register for this event, visit The New Era of CDx in Oncology: Adapting Clinical Research Strategy to Evolving Regulations.

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical ...

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH),atypical hemolytic uremic syndrome (aHUS)andgeneralized myasthenia gravis (gMG)in the U ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

Korean firms seek US FDA approval for new anticancer drugs and biosimilars Korean pharmaceutical companies renewed their ...

Kim Kyung-Ah, CEO of Samsung Bioepis, stated in her New Year's address on the 2nd, 'The U.S. launch of biosimilar drugs, ...

The global psoriasis biosimilars market is set to experience robust growth, with market value projected to rise from USD 9,228.6 million in 2024 to an impressive USD 26,679.9 million by 2034, ...

european qualifiers As the epidemic recedes, new changes in public hospitals begin I-Mab—License-in+independent R&D innovation model shows initial results R&D Daily丨Samsung Bioepis' bevacizumab ...

INR:1526. win fortune slots EU approves dolutegravir dispersible tablets for the treatment of pediatric patients aged ≥ 4 weeks and ≥ 3 kg Biogen acquires r ...